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Abstract
Background: Women with homozygous polymorphic alleles of catechol-O-methyltransferase
(COMT-LL) metabolize 2-hydroxylated estradiol, a suspected anticarcinogenic metabolite of
estrogen, at a four-fold lower rate than women with no polymorphic alleles (COMT-HH) or
heterozygous women (COMT-HL). We hypothesized that COMT-LL women exposed actively or
passively to tobacco smoke would have higher exposure to 2-hydroxylated estradiol than never-
active/never passive exposed women, and should therefore have a lower risk of breast cancer than
women exposed to tobacco smoke or with higher COMT activity.
Methods:  We used a case-only design to evaluate departure from multiplicative interaction
between COMT genotype and smoking status. We identified 502 cases of invasive incident breast
cancer and characterized COMT genotype. Information on tobacco use and other potential breast
cancer risk factors were obtained by structured interviews.
Results:  We observed moderate departure from multiplicative interaction for COMT-HL
genotype and history of ever-active smoking (adjusted odds ratio [aOR] = 1.6, 95% confidence
interval [CI]: 0.7, 3.8) and more pronounced departure for women who smoked 40 or more years
(aOR = 2.3, 95% CI: 0.8, 7.0). We observed considerable departure from multiplicative interaction
for COMT-HL genotype and history of ever-passive smoking (aOR = 2.0, 95% CI: 0.8, 5.2) or for
having lived with a smoker after age 20 (aOR = 2.8, 95% CI: 0.8, 10).
Conclusion: With greater control over potential misclassification errors and a large case-only
population, we found evidence to support an interaction between COMT genotype and tobacco
smoke exposure in breast cancer etiology.
Background
A major focus in breast cancer research has been the carci-
nogenic role of estrogens. In addition to investigating
breast cancer risk factors that influence lifetime exposure
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to estrogen (e.g. age at menarche and age at menopause)
[1,2], research is beginning to examine the environmental
and genetic factors that affect estrogen metabolism [3]. It
is known that naturally occurring estrogen (17β-estradiol)
is hydroxylated at different sites by cytochrome P450
enzymes to form catechol estrogens including 2-hydroxy-
lated (30–40%) and 16α-hydroxlated catechol estrogen
(10–12%) [4]. 16α-hydroxylated catechol estrogen has
been implicated in cell transformation and genotoxic
damage [5,6] whereas 2-hydroxylated catechol estrogen
has been postulated as a potentially anti-carcinogenic
estrogen metabolite [7-9]. Both metabolites compete with
estrogen for the estrogen receptor protein, but only the
16α-hydroxylated form has estrogenic activity [10-12].
Michnovicz et al. [13] found that active cigarette smoking
results in a substantial increase in 2-hydroxylation but lit-
tle change in 16α-hydroxylation, contributing to a higher
ratio of 2-hydroxlyated/16α-hydroxylated estradiol. Find-
ings from recent studies support the hypothesis that a
higher 2-/16α-metabolite ratio is protective against breast
cancer development [14-17].
The 2-hydroxylated catechol estrogen is metabolized by
catechol-O-methyltransferase (COMT) into non-genoto-
xic methyl ethers that are excreted from the body. There
are two COMT alleles, the wild-type allele is related to
high activity (COMT-H), and the polymorphic allele
(COMT-L) in its homozygous form is related to an
approximately four-fold lower activity [18,19]. The
COMT-L allele results from a single nucleotide polymor-
phism in the COMT gene, a G → A mutation at codon
158, which leads to a substitution of methionine for
valine [20]. Individuals homozygous for the polymor-
phism (COMT-LL) have low COMT activity, individuals
homozygous for the wild-type allele (COMT-HH) have
high COMT activity, and heterozygous individuals
(COMT-HL) have intermediate COMT activity [20]. Thus,
the COMT alleles have a codominant (or additive) effect
on metabolic activity level
This variability in methyltransferase activity related to the
polymorphism has prompted research investigating the
association between COMT genotype and breast cancer
risk. The epidemiologic studies that have examined the
association have produced inconsistent results [21-37]. A
few studies have found an elevated breast cancer risk for
women with low COMT activity [21-26]. Others have
reported no association between COMT activity and
breast cancer risk [25-35], and a few have found a
decreased breast cancer risk for women with low COMT
activity [32,37]. A recent meta-analysis concluded that
there was no major association between COMT polymor-
phisms and breast cancer risk [32].
Four earlier studies have examined the association
between COMT activity and the risk of breast cancer
within sub-groups of tobacco exposure [21,24,25,28].
Two found that the elevated breast cancer risk for women
with low COMT activity was greater among non-smokers
than smokers [21,24] and two found no meaningful dif-
ference in risk of breast cancer by COMT activity across
smoking groups [25,28].
We collected genetic and behavioral information on 502
cases of incident breast cancer arising in five different sites
across the United States. We used a case-only design to
examine the potential interaction between methylation
status – as measured by COMT genotype – and active or
passive smoking status among women with breast cancer.
We hypothesized that women who have low COMT activ-
ity and are exposed to tobacco smoke should have an
enriched concentration of 2-hydroxylated catechol estro-
gen, and should therefore have a lower smoking-related
risk of breast cancer than women with high COMT activ-
ity. The case-only design is optimal for assessing departure
from multiplicative interaction when the genotype and
environmental exposure are independent of one another.
This investigation is the largest case-only study to date to
examine the interaction between COMT genotype and
tobacco exposure history as it relates to breast cancer.
Methods
Study population
The cases of female breast cancer included in this analysis
were identified as parts of two study populations [38,39].
The first population includes cases of invasive breast can-
cer diagnosed between 1987 and 1993 among residents of
eight towns in Cape Cod, Massachusetts, and who were
reported to the Massachusetts Cancer Registry. The second
population includes cases of pathologically confirmed,
stage I or stage II breast cancer that were diagnosed from
December 1996 to September 1999 at hospitals in Rhode
Island, North Carolina, Minnesota, or Los Angeles, Cali-
fornia. The study was conducted with the approval of the
Boston University Medical Campus Institutional Review
Board.
Data collection
Buccal cell samples for genotyping
Breast cancer cases were mailed introductory letters in
2001 and 2002. A trained interviewer followed the letter
with a telephone call to answer questions and solicit par-
ticipation. Cases who agreed to participate were sent an
enrollment package containing an introductory letter,
summary information about the study, a consent form,
instructions for submitting a mouthwash sample, a safety-
sealed sample of mouthwash, and a wide-mouth sample
collection bottle. Participants collected the sample and
returned it in a postage-paid box along with theirJournal of Carcinogenesis 2006, 5:3 http://www.carcinogenesis.com/content/5/1/3
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informed consent. Buccal cells were precipitated by cen-
trifugation and stored at -70°C until a batch of 90 samples
had been collected. Batches were sent by overnight deliv-
ery on dry ice to Qiagen Genomics (Bothell, WA) for DNA
extraction and genotyping.
Qiagen genomics applied proprietary Masscode technol-
ogy to measure Masscode tags, which are low molecular
weight compounds linked to the DNA via a photocleava-
ble linker. The tag is cleaved in flow into a mass spectrom-
eter, and a Microsoft Access database converts the raw
analytical data into statistically generated genotype calls.
The assay has been validated in over one million geno-
types. Existing primers were used to characterize COMT
genotypes at the codon 158 single nucleotide polymor-
phism (SNP) in each buccal cell sample. The Qiagen gen-
otyping data characterized each participant as
homozygous wild-type, heterozygous, or homozygous
polymorphic at the SNP.
Interview data
Cases were interviewed on the telephone by trained inter-
viewers using a structured interview to obtain information
on demographic characteristics, history of active and pas-
sive exposure to cigarette smoke, and known or suspected
risk factors for breast cancer. Cases from the Cape Cod
population were interviewed between March 1997 and
March 1998. Cases from the second population were
interviewed approximately forty months after their date of
diagnosis to gather the variables used in this analysis.
Most of the exposure information related to early life char-
acteristics and events, so the differential delay between
diagnosis and interview should have little impact on the
results.
Analytic variables
COMT Genotype
We considered a woman a fast methylator if she was
homozygous for the COMT-H wild-type allele (COMT-
HH), an intermediate methylator if she was a heterozy-
gote (COMT-HL, carrying both the COMT-H wild-type
allele and the COMT-L polymorphic allele), and a slow
methylator (COMT-LL) if she was homozygous for the
COMT-L polymorphic allele. Women who were COMT-
LL were the reference genotype for all analyses.
Tobacco exposure
We considered a woman an active smoker if she reported
smoking 100 or more cigarettes in her lifetime. We con-
sidered a woman a passive smoker if she reported living
with someone who was a smoker but was never herself a
smoker. For women who reported smoking 100 or more
cigarettes in their lifetime or who lived with someone who
smoked, information on duration, intensity and timing of
exposure to tobacco smoke (active/passive) was also col-
lected. Women who were neither active nor passive smok-
ers were labeled never active/never passive smokers and
were the tobacco exposure reference group for all analy-
ses.
Covariates
In addition to smoking information, we collected infor-
mation on health and behavioral risk factors including
alcohol use, body mass index (BMI), family history of
breast cancer, history of benign breast disease, and parity.
BMI was calculated as weight divided by the square of
height (kg/m2). A woman was considered to have a first-
degree family history of breast cancer (yes/no) if she
reported that her mother, sister(s) or daughter(s) was
diagnosed with breast cancer. We defined alcohol use
according to the number of drinks a woman reported that
she "usually" had before her diagnosis: non-drinker, ≤
one drink/month, few drinks/month, few drinks/week,
almost every day, and unknown.
Analytic strategy
We examined departure from multiplicative interaction
for the association between methylation status and expo-
sure to cigarette smoke (gene-environment interaction)
among women with breast cancer. We used logistic regres-
sion analysis in SAS (Cary, NC) to quantify departure
from multiplicative interaction. In these analyses, the
odds ratios (OR) and 95% confidence intervals (CI) for
the association between smoking status and methylation
status estimate the departure of the gene and environment
joint effect from multiplicative interaction. We examined
the associations separately for active and passive smokers.
We assessed the interaction between tobacco exposure
and COMT genotype separately for high (COMT-HH) and
intermediate COMT (COMT-HL) activity as compared to
low COMT activity (COMT-LL). Women classified as both
COMT-LL and never active/never passive smokers were
the reference category for all analyses. We controlled for
the potential influence of breast cancer risk factors includ-
ing age at breast cancer diagnosis, alcohol consumption,
BMI, first-degree family history of breast cancer, geo-
graphic location (state where breast cancer diagnosis was
made, which also controls for study sample), and history
of benign breast disease using multiple variable logistic
regression. We did not assess the influence of race in the
analysis since 97% of the women in our case population
were white.
We also evaluated departure from multiplicative interac-
tion for variables describing duration, intensity and tim-
ing of active and passive smoking exposure. For active
smokers, we examined the association between methyla-
tion status and the number of packs of cigarettes smoked
per day, duration of smoking (in years), age at onset of
smoking, and time since quitting. For passive smokers, weJournal of Carcinogenesis 2006, 5:3 http://www.carcinogenesis.com/content/5/1/3
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examined the duration of passive exposure (in years) and
the age at first passive exposure.
Results
Among the Cape Cod population, 330 of 483 eligible
cases agreed to receive a sample collection kit and the
remainder refused or were unable to be contacted. Of the
330 who received a kit, 272 returned a sample and 269
samples yielded DNA that could be genotyped. Among
the second study population, 372 of 410 eligible cases
agreed to receive a sample collection kit and the remain-
der refused or were unable to be contacted. Of the 372
who received a kit, 321 returned a sample and 233 had
samples that yielded DNA that could be genotyped and
Table 1: Distribution of breast cancer risk factors by catechol-O-methyltransferase (COMT) genotype
COMT-LL (N = 80) COMT-HL (N = 248) COMT-HH (N = 174)
Characteristic N % N % N %
Age
<  5 0 8 1 02 91 32 31 3
50 – 59 5 6 25 10 13 7
60 – 69 28 35 70 28 64 37
70+ 39 49 124 50 74 43
Alcohol use
Non-drinker 12 15 39 16 26 15
≤ 1 drink/
month
20 25 51 21 47 27
Few drinks/
month
20 25 58 23 38 22
Few drinks/
week
12 15 61 25 42 24
Almost every 
day
14 17 31 13 19 11
U n k n o w n 238321
Body Mass Index 
(BMI) kg/m2
< 20.0 13 16 45 18 31 18
20.0 – 24.9 55 69 145 59 110 63
25.0 – 29.9 8 10 41 17 25 14
3 0 . 0 + 23 1 1 464
M i s s i n g236221
Family History of 
Breast Cancer *
No 62 77 188 76 130 75
Y e s 1 72 25 42 24 42 5
M i s s i n g116200
Geography
Massachusetts 37 46 134 54 98 56
California 10 13 30 12 20 11
Rhode Island 13 16 29 12 13 7
M i n n e s o t a 9 1 12 51 02 81 6
North Carolina 11 14 30 12 15 9
History of Benign 
Breast Disease
No 52 65 153 61 117 67
Y e s 2 73 49 43 85 23 0
M i s s i n g111153
Parity
Nulliparous 14 17 46 18 39 22
1 live birth 7 9 21 8 16 9
2 live births 17 21 39 16 43 25
3 live births 18 23 64 26 36 21
4 live births 13 16 39 16 15 9
5 or more live 
births
11 14 39 16 25 14
* Includes a woman's mother, sister(s) and/or daughter(s).Journal of Carcinogenesis 2006, 5:3 http://www.carcinogenesis.com/content/5/1/3
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had the requisite interview data. In both studies, 56% of
eligible participants were genotyped and included in the
analysis. The proportion of smokers among non-partici-
pants was not significantly different than among partici-
pants in either study population. The mean age was
greater among non-participants than among participants
(mean age 66 versus 61 years in the Cape Cod population,
p = 0.0001; mean age 74 versus 73 years in the second
study population, p = 0.03), reflecting greater losses-to-
follow-up and refusals among older women. Age was not,
however, associated with genotype among the partici-
pants. Furthermore, the proportions of participants who
were COMT-LL, COMT-HL, COMT-HH, active smokers,
and passive smokers did not vary significantly with their
site of enrollment. Among the genotyped controls in the
Cape Cod study, the odds ratio associating methylation
status (homozygotes versus heterozygotes) with exposure
to tobacco smoke (ever-active smoking versus all others)
equaled 1.10 (p = 0.80). This finding is consistent with
earlier studies [24,40] in which COMT genotype and
active smoking were not significantly associated among
controls.
There were 502 cases of breast cancer available for analy-
sis. Eighty women (16%) were COMT-LL, 248 (49%) were
COMT-HL and 174 (35%) were COMT-HH. Table 1 pro-
vides demographic and risk factor characteristics of the
breast cancer cases according to COMT genotype. The dis-
tribution of breast cancer risk factors did not differ mate-
rially according to COMT genotype.
We observed moderate departure from multiplicative
interaction for COMT-HL genotype and history of ever-
active smoking (adjusted odds ratio [aOR] = 1.6, 95% CI:
0.7, 3.8) but minimal departure from multiplicative inter-
action for COMT-HH genotype and history of ever-active
smoking (aOR = 1.2, 95% CI: 0.4, 3.1) compared to
COMT-LL genotype (Table 2).
Estimates for the departure from multiplicative interac-
tion between COMT genotype and the measures of inten-
sity, duration and timing of active smoking were generally
higher for COMT-HL genotype than for COMT-HH geno-
type. The departure from multiplicative interaction was
greater than the null for women with COMT-HL genotype
Table 2: Crude and adjusted odds ratios (OR) and adjusted 95% confidence intervals for departure from multiplicative interaction 
between COMT genotype and risk of active exposure to tobacco
COMT Genotype COMT-HL vs. 
COMT-LL
COMT-HH vs. 
COMT-LL
Measures of dose, 
duration and timing
COMT-LL COMT-HL COMT-HH aOR*§ (95% CI) aOR*§ (95% CI)
Never active/never 
passive ‡
12 32 24 1.0 (--) 1.0 (--)
Active smoker 39 123 85 1.6 (0.7–3.8) 1.2 (0.4–3.1)
Packs (per day)
< 1 packs 24 75 44 1.5 (0.6–3.9) 1.1 (0.4–3.1)
≥ 1 packs 15 45 40 1.6 (0.6–4.5) 1.2 (0.4–3.7)
Missing 0 3 1 † †
Duration (years)
< 40 29 83 60 1.3 (0.5–3.4) 1.1 (0.4–3.0)
40+ 9 40 24 2.3 (0.8–7.0) 1.4 (0.4–4.9)
Missing 1 0 1 † †
Age started (years)
< 22 30 95 66 1.6 (0.7–4.1) 1.1 (0.4–3.0)
≥ 22 8 28 18 1.5 (0.5–4.6) 1.5 (0.4–5.4)
Missing 1 0 1 † †
Quit smoking before 
diagnosis date (years)
Current/<5 11 17 16 0.8 (0.2–2.5) 0.7 (0.2–2.5)
5 – 15 9 29 18 1.6 (0.5–5.0) 0.8 (0.2–2.9)
> 15 17 57 39 1.5 (0.6–4.2) 1.1 (0.4–3.3)
M i s s i n g 22 0 1 2† †
* Adjusted odds ratio
§ Controlling for age, alcohol use, age at first birth, BMI, family history of breast cancer, history of benign breast disease, and geographic site of 
breast cancer diagnosis
‡ Reference group for all comparisons
† Estimates not provided for category of missing valuesJournal of Carcinogenesis 2006, 5:3 http://www.carcinogenesis.com/content/5/1/3
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when they smoked one or more packs per day (aOR = 1.6,
95% CI: 0.6, 4.5), smoked for 40 or more years (aOR =
2.3, 95% CI: 0.8, 7.0), or started smoking before age 22
(aOR = 1.6, 95% CI: 0.5, 4.6). The departure from multi-
plicative interaction was greater than the null for women
with COMT-HH genotype when they smoked one or
more packs per day (aOR = 1.2, 95% CI: 0.4, 3.7) or
smoked for 40 or more years (aOR = 1.4, 95% CI: 0.4,
4.9).
We observed considerable departure from multiplicative
interaction for COMT-HL genotype and history of ever-
passive smoking (adjusted odds ratio [aOR] = 2.0, 95%
CI: 0.8, 5.2) and moderate departure from multiplicative
interaction for COMT-HH genotype and history of ever-
passive smoking (aOR = 1.6, 95% CI: 0.6, 4.5) compared
to COMT-LL genotype (Table 3).
Estimates for the departure from multiplicative interac-
tion between COMT genotype and the measures of inten-
sity, duration and timing of passive smoking were
generally of higher magnitude for COMT-HH activity than
COMT-HL activity. The departure from multiplicative
interaction was greater than the null for women with
COMT-HL genotype who were passively exposed to
tobacco smoke for 40 or more years (aOR = 5.1, 95% CI:
1.1, 23) and who first lived with a smoker after 20 years of
age (aOR = 2.8, 95% CI: 0.8, 10). Similarly, the departure
from multiplicative interaction was greater than the null
for women with COMT-HH genotype who were passively
exposed to tobacco for 40 or more years (aOR = 5.3, 95%
CI: 1.0, 28) and who first lived with a smoker after 20
years of age (aOR = 3.3, 95% CI: 0.8, 13).
Discussion
This is the largest case-only study to evaluate the interac-
tion between catechol-O-methyltransferase (COMT)
activity and active/passive exposure to cigarette smoke
and only the second to remove women passively exposed
to tobacco smoke from the reference group, as has been
recommended for studies of the relation between tobacco
smoke and breast cancer risk [41]. Our analysis found evi-
dence to support a departure from multiplicative interac-
tion between COMT activity and smoking status. The
relative risk of breast cancer for women with the COMT-
HL genotype and a history of ever-active smoking was 1.6-
fold (95% CI: 0.7, 3.8) higher than the product of the rel-
ative risks associated with the genotype alone and smok-
ing alone. Similarly, the relative risk of breast cancer for
women with the COMT-HL genotype (aOR = 2.0, 95% CI:
0.8, 5.2) or the COMT-HH genotype (aOR = 1.6, 95% CI:
0.6, 4.5) and a history of residential exposure to passive
smoke were higher than the product of their respective rel-
ative risks associated with the genotypes alone and passive
exposure alone.
The analyses assessing the departure from multiplicative
interaction between the genotypes and intensity, duration
or timing of active and passive exposure to cigarette
smoke yielded estimates consistent with a promotional
Table 3: Crude and adjusted odds ratios (OR) and adjusted 95% confidence intervals for departure from multiplicative interaction 
between COMT genotype and risk of passive exposure to tobacco
COMT Genotype COMT-HL versus 
COMT-LL
COMT-HH versus 
COMT-LL
Measures of dose, duration and 
timing
COMT-LL COMT-HL COMT-HH aOR*§ (95% CI) aOR*§ (95% CI)
Never active/never passive‡ 12 32 24 1.0 (--) 1.0 (--)
Passive smoker 29 93 65 2.0 (0.8–5.2) 1.6 (0.6–4.5)
Duration (years)
< 40 20 69 47 1.6 (0.6–4.3) 1.1 (0.3–3.3)
40+ 8 23 16 5.1 (1.1–23) 5.3 (1.0–28)
Missing 1 1 2 † †
First lived w/smoker (age in years)
< 12 12 46 28 2.3 (0.7–7.1) 1.0 (0.3–3.9)
12 – 20 6 11 6 0.7 (0.2–3.2) 1.1 (0.2–6.9)
> 20 9 28 26 2.8 (0.8–10) 3.3 (0.8–13)
Missing 2 8 5 † †
* Adjusted odds ratio
§ Controlling for age, alcohol use, age at first birth, BMI, family history of breast cancer, history of benign breast disease, and geographic site of 
breast cancer diagnosis
‡ Reference group for all comparisons
† Estimates not provided for category of missing valuesJournal of Carcinogenesis 2006, 5:3 http://www.carcinogenesis.com/content/5/1/3
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role in breast cancer etiology for exposure to tobacco
smoke. The relative risk of breast cancer among women
with the COMT-HL or COMT-HH genotype who were
actively or passively exposed to tobacco smoke for a long
duration was higher than expected from the independent
effects of the genotype and smoking exposure. These data
are consistent with following hypothesis for the interac-
tion between COMT genotype and exposure to tobacco
smoke. First, tobacco smoke exposure increases 2-hydrox-
ylation of 17β-estradiol [13], which leads to a higher ratio
of 2-hydroxlyated/16α-hydroxylated estradiol and con-
fers a protective effect against breast cancer development
[14-17]. Second, COMT-HH or COMT-HL genotype
yields greater capacity to metabolize 2-hydroxylated estra-
diol, compared with COMT-LL genotype. Our data sug-
gest that women with long-term tobacco smoke exposure
and with the COMT-HH or COMT-HL genotype have a
higher risk of breast cancer than women with (a) long-
term tobacco smoke exposure and the COMT-LL genotype
– perhaps because these women have higher circulating
concentrations of 2-hydroxylated estradiol due to their
low COMT activity, or (b) no tobacco smoke exposure
and the COMT-HH or COMT-HL genotypes – perhaps
because these women have lower circulating concentra-
tions of 2-hydroxylated estradiol due to the absence of
tobacco smoke exposure.
Only a few studies have assessed potential modification
by cigarette smoking on the risk of breast cancer for
women with COMT-LL as compared to COMT-HH.
Lavigne et al. [21] found an elevated risk of breast cancer
for COMT-LL women compared to COMT-HH women,
and this increased risk was greater for non-smokers (OR =
2.8) than smokers (OR = 1.8), suggesting that cigarette
smoking attenuates any increased risk of breast cancer for
women with slow catechol-O-methyltransferase activity.
These findings were based on 114 cases and controls and
did not account for the influence of passive exposure to
cigarette smoke. Yim et al. [24] found that never smokers
with COMT-HL and COMT-LL genotypes were at greater
breast cancer risk as compared to never smokers with
COMT-HH genotype, OR = 2.0 and OR = 1.7, respectively.
The two remaining studies found no evidence of an inter-
action between COMT activity and active [25,28] or pas-
sive [28] smoking.
Previous studies of the association between COMT geno-
type and breast cancer risk have compared women with
one or more copies of the polymorphism to a reference
group of women homozygous for the wild-type allele
[21,24,25,28]. In our study, we used women homozygous
for the polymorphism as the reference group to clarify the
interpretation of our effect estimates. Below the null
departure from multiplicative interaction is difficult to
interpret because it may reflect sub-multiplicative interac-
tion that is still super-additive. In contrast, departure from
multiplicative interaction above the null reflects positive
interaction on both the additive and multiplicative scales.
The genotyping procedures employed in this analysis
have superior accuracy compared to PCR-RFLP techniques
employed in three of the previous studies [21,24,25].
Consequently, the rates of misclassification of methyla-
tion status in this study should be less than rates in the
previous studies employing less accurate PCR-RFLP tech-
niques. Misclassification of either variable involved in an
assessment of interaction in case-control studies can give
rise to the appearance of interaction when, in fact, there is
none [42].
Our analysis of interaction using case-only data provides
greater control over the impact of potential misclassifica-
tion errors, because there are only two variables central to
the analysis that are susceptible to misclassification –
COMT genotype and smoking status. As described above,
the impact of misclassification is less predictable in three
of the previous case-control analyses. It is therefore possi-
ble that previous studies evaluating the interaction of
COMT genotype and exposure to tobacco smoke in rela-
tion to breast cancer risk may have generated biased esti-
mates of interaction. By using a more accurate genotyping
method and by implementing a case-only design, this
analysis provides a more valid assessment of departure
from multiplicative interaction between COMT genotype
and exposure to tobacco smoke in relation to breast can-
cer.
Weighing against this advantage of the case-only design is
the limitation that only departure from multiplicativity
can be assessed. Many epidemiologists weigh departure
from additive interaction more heavily, arguing that the
additive scale corresponds better to the biologic meaning
of synergistic effects [43]. A further limitation of the case-
only design is its reliance on the assumption that the
genetic polymorphisms and environmental exposure are
independent of one another [44]. Violations of this
assumption can substantially distort the estimates of
interaction. However, COMT polymorphisms and smok-
ing history were not associated among the genotyped con-
trols in the Cape Cod study or among the controls in
earlier studies [24,40]. The absence of association sup-
ports the independence assumption required to validly
estimate departure from multiplicativity with the case-
only design.
Finally, these results must be interpreted with the follow-
ing limitation in mind. Only 56% of eligible cases were
available for analysis. Participation was not related to
smoking status and although participation was related to
age, age was not related genotype. We expect that theJournal of Carcinogenesis 2006, 5:3 http://www.carcinogenesis.com/content/5/1/3
Page 8 of 9
(page number not for citation purposes)
selection of participants introduced no substantial bias,
although we acknowledge that our study of breast cancer
survivors may have influenced the estimates of effect in
ways that we are unable to anticipate.
Conclusion
This large case-only analysis is only the second to investi-
gate the interaction between COMT genotype and expo-
sure to tobacco smoke as related to breast cancer risk
while removing women passively exposed to tobacco
smoke from the reference group. The combination of the
most complete genotyping data and the large case-only
design provided important advantages in this study,
whose results suggest potential interaction between
COMT genotype and tobacco smoke exposure in breast
cancer etiology, perhaps related to the coaction of smok-
ing and genotype on the concentration of 2-hydroxylated
catechol estrogen. Weighing against this interpretation is
the potential for an unanticipated bias to have arisen by
selection of breast cancer survivors from among the inci-
dent cases.
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